Exagen, Inc. (Nasdaq: XGN) is a leading provider of autoimmune testing with a mission to provide clarity in decision-making and improve clinical outcomes through its innovative portfolio. Flagship product AVISE® CTD enables clinicians to more effectively diagnose complex autoimmune conditions earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring.